CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 8, 2017--
Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Ph.D.,
Synlogic’s president and chief executive officer, will present at the
following conferences in November:
The Stifel 2017 Healthcare Conference at 11:45 am ET on November 15th,
2017, in New York City
The Jefferies 2017 London Healthcare Conference at 5:20 pm GMT (12:20
pm ET) on November 16th, 2017, in London, UK
The 29th Annual Piper Jaffray Healthcare Conference at
11:00 am on November 29th, 2017, in New York City
Live webcasts of each of the presentations can be accessed under “Event
Calendar” in the Investors & Media section of the Company’s website.
Archived webcast recordings will be available on the Synlogic website
for approximately 30 days after each event.
Synlogic is pioneering the development of a
novel class of living treatments, Synthetic BioticTM
medicines, based on its proprietary drug development platform.
Synlogic’s initial pipeline includes Synthetic Biotic medicines for the
treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD)
and Phenylketonuria (PKU). In addition, the company is leveraging the
broad potential of its platform to create Synthetic Biotic medicines for
the treatment of more common diseases, including liver disease,
inflammatory and immune disorders, and cancer. Synlogic is collaborating
with AbbVie to develop Synthetic Biotic-based treatments for
inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005963/en/
Elizabeth Wolffe, Ph.D.,